Aktienanalyse zu Amphastar Pharmaceuticals, Inc. (AMPH)AMPHAmphastar Pharmaceuticals, Inc.

Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells active pharmaceutical ingredient (API) products. Most of the Company's finished products are contracted and distributed through group purchasing organizations, drug wholesalers, and drug retailers. The Company manufactures and sells over 25 prescription pharmaceutical products, and one over-the-counter product, Primatene MIST. Its marketed products include BAQSIMI (glucagon) nasal powder 3mg, Glucagon for Injection Emergency Kit, Enoxaparin, Naloxone, Cortrosyn, Amphadase, and Epinephrine injection. It manufactures and sells two API products: Recombinant Human Insulin (RHI API) and porcine insulin API. It is also focused on generic and proprietary product candidates in the injectable, inhalable, topical, and intranasal markets. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Amphastar Pharmaceuticals Inc is not a good buy right now due to several concerning factors. The current price is $25.87, which is above the latest analyst target of $20 from BofA, indicating potential downside. Additionally, the company has a low RSI of 46.789, suggesting it is neither overbought nor oversold, but the recent trend shows a 5-day change of -2.82%, indicating weakness. Furthermore, insider selling has increased by 4073.82%, which raises red flags about confidence in the company's future performance. The main risk is the declining adjusted operating margin, which has decreased by 10.9 percentage points over the last two years, indicating profitability concerns.

6 analysts cover AMPH: 4 rate it Buy, 2 Hold and 0 Sell. The average price target is 32.00.